Mazdutide: What It Is and What It’s Known For
Mazdutide is one of the most clinically advanced next-generation metabolic peptides of 2026 — a GLP-1/glucagon dual receptor agonist with the largest Phase 3 evidence base of any compound in its class. Here is what it is, what it is known for, and what to look for when sourcing it.
What is Mazdutide?
Mazdutide (developmental code IBI362, also known as LY3305677) is a synthetic peptide that acts as a dual agonist at the glucagon-like peptide-1 (GLP-1) receptor and the glucagon (GCGR) receptor. It is structurally based on oxyntomodulin — a naturally occurring gut hormone that itself engages both the GLP-1 and glucagon receptors — making it what researchers call an oxyntomodulin analogue. It is co-developed by Innovent Biologics and Eli Lilly, and is supplied for research as a lyophilised powder for reconstitution before use.
What is it known for?
Mazdutide is best known within research circles for having the deepest clinical dataset among GLP-1/glucagon dual agonists. Its development has run through the GLORY programme (obesity) and the DREAMS programme (type 2 diabetes models), spanning multiple Phase 3 studies — an unusually broad evidence base for a compound in this category. Much of that research has been conducted in Chinese populations, which gives mazdutide a distinct geographic and regulatory profile compared with globally-focused compounds like survodutide.
Its oxyntomodulin-analogue design is a particular point of research interest, because it grounds the dual-agonist concept in a naturally occurring hormone rather than a fully synthetic construct.
The GLP-1/Glucagon Dual Mechanism
Mazdutide engages two pathways at once. The GLP-1 arm is associated with appetite suppression, slowed gastric emptying, and glucose-dependent insulin secretion. The glucagon (GCGR) arm is studied for its role in energy expenditure and hepatic fat oxidation. The research rationale for combining them is that glucagon-driven energy expenditure may add to GLP-1-driven appetite reduction — potentially producing broader metabolic effects than a single-pathway agonist.
This places mazdutide in the same mechanistic family as survodutide (also GLP-1/glucagon), and distinct from the triple-agonist design of Retatrutide, which adds a third receptor target (GIP).
How It Compares to Related Compounds
Mazdutide’s closest mechanical cousin is survodutide — both are GLP-1/glucagon dual agonists. The headline difference across the wider next-generation group is receptor count: mazdutide and survodutide are dual agonists, while Retatrutide is a triple agonist. Mazdutide is frequently noted for the sheer size of its Phase 3 evidence base relative to peers. As with all compounds in this space, no published head-to-head trials exist between them as of 2026, so any cross-compound comparison is indirect and drawn from separate studies with different populations, doses, and endpoints.
Properties Researchers Value
- Oxyntomodulin-analogue design — grounded in a naturally occurring dual-receptor gut hormone.
- Large clinical dataset — the broadest Phase 3 evidence base among GLP-1/glucagon dual agonists.
- Dual-pathway mechanism — engages both GLP-1 and glucagon receptors.
- Reconstitution — supplied lyophilised and dissolves readily in bacteriostatic water.
What to Look for When Sourcing
As a long, acylated peptide, mazdutide is more complex to synthesise than shorter sequences, which makes purity verification important. Look for an independent Certificate of Analysis confirming HPLC purity (≥98%) and mass spectrometry identity from a named third-party laboratory. Our guide on why COA testing matters explains what to check.
Reconstitution
Mazdutide is supplied lyophilised and dissolved in bacteriostatic water before use. Our reconstitution guide covers the full process, and the Peptide Calculator handles concentration and draw-volume calculations.
Where It Sits in the Research Landscape
Mazdutide is part of the 2026 shift in metabolic peptide research toward multi-receptor strategies. For the broader picture, see our overview of triple agonists as the next frontier after dual agonists, and our comparison of Tirzepatide vs Retatrutide.
Compounds Referenced in This Article
This article is provided for educational purposes for laboratory research professionals. Mazdutide is an investigational compound and is not approved by the MHRA, FDA, or any equivalent regulatory body. All Revial Labs compounds are supplied strictly for laboratory research use only and are not for human or veterinary use.
